Xponance Inc. Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Xponance Inc. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 85,725 shares of the medical device company’s stock after selling 2,878 shares during the period. Xponance Inc.’s holdings in DexCom were worth $10,638,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DXCM. Cary Street Partners Investment Advisory LLC lifted its position in shares of DexCom by 11.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the period. CX Institutional acquired a new position in shares of DexCom during the 4th quarter worth approximately $286,000. Cerity Partners LLC raised its position in shares of DexCom by 5,791.0% during the 4th quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares during the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $57,000. Finally, Intelligence Driven Advisers LLC acquired a new position in shares of DexCom during the 3rd quarter worth approximately $525,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DXCM. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. UBS Group lifted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Stock Down 0.1 %

Shares of NASDAQ:DXCM traded down $0.18 during midday trading on Friday, hitting $134.12. 233,666 shares of the company’s stock traded hands, compared to its average volume of 2,947,279. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The company has a market cap of $51.71 billion, a PE ratio of 102.52, a P/E/G ratio of 2.30 and a beta of 1.20. The firm’s fifty day moving average price is $129.35 and its two-hundred day moving average price is $116.41. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business’s quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares in the company, valued at approximately $9,618,227.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares in the company, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.